185 related articles for article (PubMed ID: 36692895)
1. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Havrdova EK; Patti F; Shaygannejad V; Ozakbas S; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Girard M; Duquette P; Terzi M; Boz C; Grand'Maison F; Hamdy S; Sola P; Ferraro D; Grammond P; Turkoglu R; Buzzard K; Skibina O; Yamout B; Altintas A; Gerlach O; van Pesch V; Blanco Y; Maimone D; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Barnett M; Hughes S; Sa MJ; Solaro C; Kappos L; Ramo-Tello C; Cristiano E; Hodgkinson S; Spitaleri D; Soysal A; Petersen T; Slee M; Butler E; Granella F; de Gans K; McCombe P; Ampapa R; Van Wijmeersch B; van der Walt A; Butzkueven H; Prevost J; Sinnige LGF; Sanchez-Menoyo JL; Vucic S; Laureys G; Van Hijfte L; Khurana D; Macdonell R; Gouider R; Castillo-Triviño T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Deri N; Al-Harbi T; Fragoso Y; Csepany T; Perez Sempere A; Trevino-Frenk I; Schepel J; Moore F; Kalincik T
Eur J Neurol; 2023 Apr; 30(4):1014-1024. PubMed ID: 36692895
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for people with multiple sclerosis.
Filippini G; Kruja J; Del Giovane C
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
[TBL] [Abstract][Full Text] [Related]
3. Untreated patients with multiple sclerosis: A study of French expert centers.
Moisset X; Fouchard AA; Pereira B; Taithe F; Mathey G; Edan G; Ciron J; Brochet B; De Sèze J; Papeix C; Vermersch P; Labauge P; Defer G; Lebrun-Frenay C; Moreau T; Laplaud D; Berger E; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Créange A; Camdessanché JP; Bakchine S; Maurousset A; Hankiewicz K; Pottier C; Maubeuge N; Dimitri Boulos D; Nifle C; Vukusic S; Clavelou P;
Eur J Neurol; 2021 Jun; 28(6):2026-2036. PubMed ID: 33650261
[TBL] [Abstract][Full Text] [Related]
4. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
5. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E; Fonderico M; Iaffaldano P; Pastò L; Razzolini L; Bellinvia A; De Luca G; Ragonese P; Patti F; Brescia Morra V; Cocco E; Sola P; Inglese M; Lus G; Pozzilli C; Maimone D; Lugaresi A; Gazzola P; Comi G; Pesci I; Spitaleri D; Rezzonico M; Vianello M; Avolio C; Logullo FO; Granella F; Salvetti M; Zaffaroni M; Lucisano G; Filippi M; Trojano M; Amato MP;
JAMA Neurol; 2022 Sep; 79(9):869-878. PubMed ID: 35877104
[TBL] [Abstract][Full Text] [Related]
6. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Kalincik T; Diouf I; Sharmin S; Malpas C; Spelman T; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Jokubaitis V; van der Walt A; Grand'Maison F; Sola P; Ferraro D; Shaygannejad V; Alroughani R; Hupperts R; Terzi M; Boz C; Lechner-Scott J; Pucci E; Van Pesch V; Granella F; Bergamaschi R; Spitaleri D; Slee M; Vucic S; Ampapa R; McCombe P; Ramo-Tello C; Prevost J; Olascoaga J; Cristiano E; Barnett M; Saladino ML; Sanchez-Menoyo JL; Hodgkinson S; Rozsa C; Hughes S; Moore F; Shaw C; Butler E; Skibina O; Gray O; Kermode A; Csepany T; Singhal B; Shuey N; Piroska I; Taylor B; Simo M; Sirbu CA; Sas A; Butzkueven H;
Neurology; 2021 Feb; 96(5):e783-e797. PubMed ID: 33372028
[TBL] [Abstract][Full Text] [Related]
7. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
[TBL] [Abstract][Full Text] [Related]
8. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
[TBL] [Abstract][Full Text] [Related]
9. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
11. Relapses add to permanent disability in relapsing multiple sclerosis patients.
Koch-Henriksen N; Sørensen PS; Magyari M
Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
[TBL] [Abstract][Full Text] [Related]
12. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
[TBL] [Abstract][Full Text] [Related]
13. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
16. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
19. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
